. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: Brain Pathol. 2018 Oct 17;29(1):126–140. doi: 10.1111/bpa.12646

Table 2.

Summary of immunophenotypic and molecular features of pilocytic astrocytomas with anaplasia (PA-A).

Alteration	PA-A	PA precursor
ALT	25/36 (69%)	9/14
ATRX (IHC) loss	20/35 (57%)	7/11
IDH1 (R132H)	0/32 (0%)	NA
BRAF duplication	8/26 (31%)	8/14
BRAF (V600E)	0/31 (0%)^*	NA
NF1 status	12/36 (33%)^#	3/19
H3-K27M	5/32 (16%)	2/14
CDKN2A	3/18 (17%)^&	NA
P53 (strong IHC)	6/17 (35%)	NA

ALT=alternative lengthening of telomeres, NF1=neurofibromatosis type 1

a single case had an activating mutation in BRAF (non V600E) by sequencing (BRAF p.D594G).

A total of 8 patients satisfied clinical criteria for NF1 while four additional patients demonstrated NF1 mutations in their tumors by sequencing studies.

A total of 3 patients had homozygous deletion as tested by FISH (n=12), NGS (n=6), or both (n=1).